Cancer treatment with 237 CAR-T cell based therapeutics recognizing the Tn epitope
AssigneesThe University of Chicago, The Board of Trustees of the University of Illinois
InventorsHans Schreiber, David Kranz, Karin Schreiber, Yanran He, Preeti Sharma
Life of this patent
Estimating the term…
Abstract
The disclosure provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs, as well as methods of identifying cancer subjects and cancer subject sub-populations amenable to anti-Tn immunotherapy and methods of treating cancer.
Claims17
A chimeric antigen receptor (CAR) that specifically binds a Tn glycopeptide comprising:
- (a) a single chain variable fragment (scFv) that specifically binds a Tn glycopeptide, wherein the scFv comprises a heavy chain complementarity determining region 1 (CDRH1), a CDRH2, a CDRH3, a light chain complementarity determining region 1 (CDRL1), and a CDRL2 of SEQ ID NO:
- 19, and a CDRL3 comprising a variant sequence of TTWAP, STWAP, STWSP, STWGP, STWQP, STWEP, SVWEP, STWVP, STHQP, SLGQP, or TNGKP at positions 96-100 of SEQ ID NO:
- 19;
- and
- (b) a T-cell signaling domain.
A soluble cancer-specific 237 single chain variable fragment (scFv) variant that specifically binds a Tn glycopeptide comprising a heavy chain complementarity determining region 1 (CDRH1), a CDRH2, a CDRH3, a light chain complementarity determining region 1 (CDRL1), and a CDRL2 of SEQ ID NO:19, and a variant of a CDRL3 comprising a variant sequence of TTWAP, STWAP, STWSP, STWGP, STWQP, STWEP, SVWEP, STWVP, STHOP, SLGQP, or TNGKP at positions 96-100 of SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.